Startpage

  • Isofol Medical AB (publ) appoints Jenny Sundqvist as Chief Commercial Officer

    GOTHENBURG, Sweden, December 10, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced the appointment of Jenny Sundqvist…

    by

  • Isofol Medical AB (publ) invites to an audiocast on December 6 at 08.00 a.m. CET

    GOTHENBURG, Sweden, December 5, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced on December 3 that the ongoing…

    by

  • Isofol Medical AB (publ) will not reach 300 PFS events in the AGENT study with current censoring rules based on FDA decision

    GOTHENBURG, Sweden, December 3, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and…

    by

  • Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)

    GOTHENBURG, Sweden, November 23, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and Drug…

    by

  • Isofol appoints nomination committee ahead of the Annual General Meeting 2022

    GOTHENBURG, Sweden, November 19, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that…

    by

  • Isofol Medical AB (publ) publishes interim report for January – September 2021

    GOTHENBURG, Sweden, November 11, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report…

    by

  • Trading in Isofol’s shares commences today on Nasdaq Stockholm

    GOTHENBURG, Sweden, October 21, 2021 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that…

    by